Canaccord Genuity cuts Ultragenyx Pharma PT to $37
Canaccord Genuity maintained a Buy rating on Ultragenyx Pharma while cutting its price target to $37.00 per share from $83.00.
Ratings actions GMT) Ultragenyx Pharma Is Maintained at Buy by Canaccord GenuityRatings actions